Metformin, a drug commonly used for the treatment of patients with type 2 diabetes, reduced galectin-3 levels in adipocytes and monocytes and correlated with reduced serum galectin-3 levels [65,66]. Here, LGALS3 is linked to type 2 diabetes mellitus.